ImmunOs’ immune-oncology pipeline is based on its ability to engage both the innate and the adaptive immune system with a single, multitasking compound that remodels the tumor’s microenvironment. As a result, the tumor can be targeted both by immunotherapies and the body’s own immune system.
The Company´s first compounds are HLA-based proteins which bind to receptors of LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) families.
The Company´s lead program IOS-1002 is a potent LILRB and KIR-modulating agent with potential in multiple solid and liquid tumor indications. It is designed as a potential first-line monotherapy and as a combination therapy to improve medical outcomes in non-responders to adaptive immunity agents. IOS-1002 differentiates from competitor approaches as it targets multiple LILRB receptors and a KIR receptor instead of a single receptor.
In various animal models, the compound has led to tumor shrinkage (up to 90%) and to improved survival.
The compound is expected to enter clinical trials in 2022. A Phase 1a/1b trial will be designed to deliver proof-of-concept in a monotherapy trial of IOS-1002 with an expansion cohort option for combination with anti-PD1 treatment (pembrolizumab).
The Company also explores the combination of its products with diverse types of complementary cancer therapies, such as chemotherapy, vaccines, etc.